Key result
CYP2C19 genotype testing has doubtful clinical utility for guiding antiplatelet prescribing.
Why the study?
Does CYP2C19 genotype testing improve clinical outcomes when guiding antiplatelet prescribing?
Does CYP2C19 genotype testing improve clinical outcomes when guiding antiplatelet prescribing?
Answers are grounded in this paper and cite their sources.
The clinical utility of CYP2C19 genotype testing for guiding antiplatelet therapy is questioned by a new analysis.
A new analysis casts doubt on the clinical utility of CYP2C19 genotype testing to help guide antiplatelet prescribing
No takes yet. Share an insight, caveat, or question.
Holmes et al. (2011) studied this question. CYP2C19 genotype testing has doubtful clinical utility for guiding antiplatelet prescribing.
Synapse has enriched 10 related papers. Consider them for comparative context: